World Tuberculosis Day Webinar 2023
Welcome Message
In order to commemorate World Tuberculosis Day 2023 (https://www.who.int/campaigns/world-tb-day/), MDPI is launching a special webinar to raise public awareness about the devastating health, social and economic consequences of tuberculosis (TB) and to step up efforts to end the global TB epidemic.
We are very much looking forward to seeing you at the World Tuberculosis Day Webinar 2023. Please find below an up-to-date outline of invited speakers.
Conference Secretariat
Event Host
Journal Relations Specialist of Biomedicines (ISSN: 2227-9059) and Reports (ISSN: 2571-841X),
MSc in Molecular Biotechnology
Journal Relations Specialist of Vaccines (ISSN 2076-393X),
MSc in Ecology
Invited Speakers
E.O. Ospedali Galliera,
Section Board Member of Antibiotics ( ISSN: 2079-6382 )
TB and prisons
drug-drug interactions and pharmacodynamics; antimicrobial stewardship; tuberculosis; RR/MDR/XDR- tuberculosis; anti-tubercular drugs; sepsis; antibiotic therapy in infectious diseases
Department of Chemistry, Colorado State University,
Editorial Board Member of IJMS (ISSN: 1422-0067),
Editorial Board Member of Inorganics (ISSN: 2304-6740)
Lipoquinones and specifically menaquinones are a class of hydrophobic lipid molecules that are essential for the survival of the Mycobacteria by shuttling electrons between membrane-bound protein complexes within the electron transport chain. This process leads to ATP formation. We have studied the properties of menaqinones mainly focusing on truncated compounds and the mode of action of several of the enzymes such as MenJ. My group and I study the properties of these simply compounds, and their interactions with numerous enzymes with the intention to develop new drug development targets.
Prof. Dr. Debbie Crans's interest in the fundamental chemistry and biochemistry of drugs with particular interest in vanadium and other transition metal ions as metals in medicine and their mechanisms of toxicity. New projects involve menaquinone metabolism and inhibition of electron transport in tuberculosis bacteria and characterization of amyloid interactions with metal ions and their aggregation leading to a better understanding of new and existing drugs. For more information, please check: https://cranslab.colostate.edu/crans-brief-resume/
vanadium; metals in medicine; drugs and biologically active compounds; lipid and lipid model interfaces; pharmaceutically active compounds; cancer; diabetes; tuberculosis; hydrophobic compounds; spectroscopy; transition metals; reverse micelles; chemistry
Chemistry Department, Alexandru Ioan Cuza University of Iasi,
Section Board Member of Molecules (ISSN: 1420-3049)
New (Di-)Azine and (Di-)Azole with antituberculosis activity
Dr. Mangalagiu is a professor of organic and medicinal chemistry and Vice-Rector with research at Alexandru Ioan Cuza University of Iasi, Romania. He has nearly 35 years of experience in the research, focused in the area of (Aza) Heterocycles Compounds. He has over 200 papers, over 2000 citations (H-index=28), 15 patents, 6 international chapter books, etc. He was Visiting Professor and/or invited speaker to prestigious foreign universities (University of Florence, Universite D’Angers, Ludwig Maximilianus University Munchen and Technische Universität Braunschweig), awarded with numerous prizes and honours: DAAD and NATO award, “Costin D. Nenitescu Medal” (Romanian Society of Chemistry), “Al.I.Cuza University Award in Research”, “Grand Prize Euroinvent” (Euroinvent, Romania), Special Award of Croatian Association of Inventors, etc. Web site: http://teclu.chem.uaic.ro/mangalagiu; Additional web site: http://a302.chem.uaic.ro/
iMed.ULisboa – Instituto de Investigação do Medicamento, Faculdade de Farmácia, Universidade de Lisboa,
Guest Editor of IJMS ( ISSN: 1422-0067)
On the evolution of drug resistant tuberculosis: what have we learned from MDR-TB in Portugal?
Prof. Dr. João Perdigão is PI at the Bacterial Pathogenomics and Drug Resistance Laboratory, Research Institute for Medicines from Faculty of Pharmacy of Universidade de Lisboa (iMed) His current research interests are aimed at the elucidation of the bacterial mechanisms underlying diversification and adaptation processes with epidemiological and clinical relevance. These have been mostly focused on the study of the evolution of Mycobacterium tuberculosis multidrug resistant strains; genomic epidemiology and comparative genomics of clinical isolates circulating in Portugal and Portuguese-speaking countries.
tuberculosis and gram-negative genomic epidemiology and drug resistance
Research Institute of Health and Welfare, KIBI International University,
Emeritus Professor, Tohoku University,
Editor-in-Chief of Reports (ISSN: 2571-841X ),
Editorial Board Member of Vaccines (ISSN: 2076-393X),
Guest Editor of Biomolecules (ISSN: 2218-273X),
Section Board Member of IJMS (ISSN: 1422-0067)
Roles of matricellular proteins (Osteopontin and Galcetins) as severity markers in AIDS/TB.
Research Background: Immunological aspects of ATL and AIDS. Diagnosis of tuberculosis by immunological methods. Roles of matricellular proteins in tropical infectious diseases such as dengue, malaria and AIDS/TB.
Hematology, Respiratory Medicine, Infectious diseases
Session 1: 9:00 am-10:10 am (CET)
This is a FREE webinar. The number of participants to the live session is limited but the recording will be made available on Sciforum shortly afterwards. Registrations with academic institutional email addresses will be prioritized.
Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.
|
Speaker/Presentation |
CET |
|
Webinar Introduction |
9:00 am – 9: 10 am |
|
Prof. Dr. Toshi Hattori Roles of matricellular proteins (Osteopontin and Galcetins) as severity markers in AIDS/TB |
9: 10 am – 9: 40 am |
|
Prof. Dr. Emanuele Pontali TB and prisons |
9: 40 am – 10: 10 am |
Session 2: 15:00 pm-16:40 pm (CET)
This is a FREE webinar. The number of participants to the live session is limited but the recording will be made available on Sciforum shortly afterwards. Registrations with academic institutional email addresses will be prioritized.
Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.
|
Speaker/Presentation |
CET |
|
Webinar Introduction |
15:00 pm – 15: 10 pm |
|
Prof. Dr. Debbie C. Crans Menaquinones, molecules essential for Mycobacterial function: strategies to combat bacterial spread |
15: 10 pm – 15: 40 pm |
|
Prof. Dr. João Perdigão On the evolution of drug resistant tuberculosis: what have we learned from MDR-TB in Portugal? |
15: 40 pm – 16: 10 pm |
|
Prof. Dr. Ionel Mangalagiu New (Di-)Azine and (Di-)Azole with antituberculosis activity |
16: 10 pm – 16: 40 pm |
Special Issues
Molecules:
Research Progress and Application of Natural Compounds
edited by Claudiu N. Lungu and Ionel Mangalagiu
submission deadline: 30 April 2023
Antitubercular Drug Discovery: Implication and Challenges
edited by Jonathan Sellars and Alistair Brown
submission deadline: 30 June 2023
IJERPH:
TB- and HIV-Associated Stigma
edited by Denise H. Evans, Dorina Onoya and Graeme Hoddinott
submission deadline: 31 December 2023
Pathogens:
Resistance, Tolerance, Persistence: Drug Evasion Strategies of Tuberculosis Treatment Failure
edited by Shuyi Ma
submission deadline: 10 June 2023
Tuberculosis and Nontuberculous Mycobacterial Infections in the Immunocompromised Host
edited by Daria Podlekareva, Ole Kirk and Thomas Theo Brehm
submission deadline: 15 October 2023
